Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289361 | 0.80 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL6706802 | 0.74 | NPC1 (0.51) | LMNAPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL6706893 | 0.69 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL6694969 | 0.69 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL6705942 | 0.68 | ALDH1A1 (0.48) | ALDH1A1PTGER4MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL6288755 | 0.68 | TP53 (0.45) | LMNAPOLBALDH1A1PTGER4MAPT | |
| SCHEMBL6292189 | 0.65 | POLB (0.46) | LMNAPOLBALDH1A1PTGER4TP53 | |
| SCHEMBL4747957 | 0.64 | NR1H4 (0.81) | LMNAPOLBKMT2AHPGDMAPK1 | |
| SCHEMBL13460269 | 0.64 | LMNA (0.62) | LMNAPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL104431 | 0.64 | RAB9A (0.75) | LMNAPOLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | LMNA 1817/4885POLB 2737/4885ALDH1A1 337/4885 |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | LMNA 2847/4885POLB 678/4885ALDH1A1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.